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WHO, in collaboration with UNAIDSs and UNICEF,
report annually on progress in the different HIV/AIDS
interventions. In 2010, more than 6.6 million people had
access to Antiretroviral Therapy (ART), in low-and –
middle income countries, representing a 17-fold increase
in less than 7 years. This is one of the most successful
public health achievements.
However, this represents less than 50% coverage of
needs. The 2010 global commitment of Universal Access
to ART has not been achieved.
The presentation will address determinants of progress
and of inequalities in access to ART, according to geogra-
phical and population criteria. West and Central Africa as
well as Eastern Europe and Central Asia are reporting low
coverage rates compared to other similar regions. Cover-
age among children less than 15 years old is much lower
than adult coverage (23% versus 51%). Access to ART for
intravenous drug users is very low in most countries. In
many settings, access for people in rural areas is much
more limited than in public area.
Closing the gap in access to ART will need implement-
ing huge efforts to reduce inequities in access. A compre-
hensive approach should include improvement of health
delivery systems, decentralization of care, simplification of
treatment and laboratory monitoring. It will need also to
address essential human right issues, including stigmatiza-
tion and discrimination of key populations who currently
do not have access to testing and counseling and other
essential interventions.
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